Figure 5
![Medical Research Council FOCUS 4 clinical trial design [47].](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/oncolo/20/12/10.1634_theoncologist.2015-0263/2/oncolo_20_12_1448_f6.jpeg?Expires=1749708588&Signature=qevzPLFycKeYYq74mDO~GLT5xZXXRkXiTz-yWNJT3KaD8TwZ~cTUNTsYDhBopLidM1Q0dyugt3eEj9JcNiftexv1FpcVmsLq0fx6cqyN5L0popWBwS4BSDlaeVV8TqV6MlbilJSvRLvNR9yBdnMUMTk6LgednOlFkRS5Tiwq980Dy7jklMakazgwoO8nVVtXXKR0tWXDCVJZALGqQLlM3p5-1Opv0tSzq-uJiqyuR5n3p6PdGfkbTbj4hnArPRyl-mGb3J2VIwnlU5O5no7yW8xwre~N4Ls1Fc-RBOJQNVoKe-o8jEWwA2hLLz5EtYy4KadcNI3nRUh1~DYESH4D1A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Medical Research Council FOCUS 4 clinical trial design [47].
Abbreviations: CRC, colorectal cancer; FFPE, formalin-fixed, paraffin-embedded; IHC, immunohistochemistry; MMR, mismatch repair; OS, overall survival; P, placebo; PFS, progression-free survival; Rx, prescription.
